Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Research Alliance Corporation III
13G
RACC · G75226103
|
6.5% |
9/11/2026
Event 9/4/2026
|
|||
| Great Point Partners, LLC | 6.5% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.5% | ||||
| Ms. Lillian Nordahl | 6.5% | ||||
|
JATT III Acquisition Corp
13G
JTTT · G5080G109
|
5.8% |
9/2/2026
Event 8/26/2026
|
|||
| Great Point Partners, LLC | 5.8% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.8% | ||||
| Ms. Lillian Nordahl | 5.8% | ||||
|
Promis Neurosciences Inc.
13G/A
Amendment 1
PMN · 74346M505
|
7.7% |
8/14/2026
Event 6/30/2026
|
|||
| Great Point Partners, LLC | 7.7% | ||||
| Dr. Jeffrey R. Jay, M.D. | 7.7% | ||||
| Ms. Lillian Nordahl | 7.7% | ||||
|
JATT II Acquisition Corp.
13G/A
Amendment 1
JATT · G50765109
|
6.2% |
8/14/2026
Event 6/30/2026
|
|||
| Great Point Partners, LLC | 6.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.2% | ||||
| Ms. Lillian Nordahl | 6.2% | ||||
|
SCYNEXIS, Inc.
13G/A
Amendment 1
SCYX · 811292309
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
Amanat Acquisition Corp
13G/A
Amendment 1
AMAN · G0375M101
|
6.7% |
8/14/2026
Event 6/30/2026
|
|||
| Great Point Partners, LLC | 6.7% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.7% | ||||
| Ms. Lillian Nordahl | 6.7% | ||||
|
Amanat Acquisition Corp
13G
AMAN · G0375M101
|
5.2% |
5/27/2026
Event 5/19/2026
|
|||
| Great Point Partners, LLC | 5.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||||
| Ms. Lillian Nordahl | 5.2% | ||||
|
Promis Neurosciences Inc.
13G
PMN · 74346M505
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 7
CNTX · 21077P108
|
2.4% |
5/15/2026
Event 3/31/2026
|
|||
| Great Point Partners, LLC | 2.4% | ||||
| Dr. Jeffrey R. Jay, M.D. | 2.4% | ||||
| Ms. Lillian Nordahl | 2.4% | ||||
|
Zura Bio Limited
13G/A
Amendment 3
ZURA · G9TY5A101
|
4.4% |
5/15/2026
Event 3/31/2026
|
|||
| Great Point Partners, LLC | 4.4% | ||||
| Dr. Jeffrey R. Jay, M.D. | 4.4% | ||||
| Ms. Lillian Nordahl | 4.4% | ||||
|
JATT II Acquisition Corp.
13G
JATT · G50765109
|
6.4% |
4/24/2026
Event 4/17/2026
|
|||
| Great Point Partners, LLC | 6.4% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.4% | ||||
| Ms. Lillian Nordahl | 6.4% | ||||
|
SCYNEXIS, Inc.
13G
SCYX · 811292200
|
10.0% |
4/7/2026
Event 3/31/2026
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
Sol-Gel Technologies Ltd.
13G
SLGL · M8694L137
|
8.5% |
3/31/2026
Event 3/24/2026
|
|||
| Great Point Partners, LLC | 8.5% | ||||
| Dr. Jeffrey R. Jay, M.D. | 8.5% | ||||
| Ms. Lillian Nordahl | 8.5% | ||||
|
ProMIS Neurosciences Inc.
13G/A
Amendment 5
PMN · 74346M505
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 6
CNTX · 21077P108
|
5.1% |
2/17/2026
Event 12/31/2025
|
|||
| Great Point Partners, LLC | 5.1% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.1% | ||||
| Ms. Lillian Nordahl | 5.1% | ||||
|
Inventiva S.A.
13G/A
Amendment 2
F5R343107
|
3.5% |
2/17/2026
Event 12/31/2025
|
|||
| Great Point Partners, LLC | 3.5% | ||||
| Dr. Jeffrey R. Jay, M.D. | 3.5% | ||||
| Ms. Lillian Nordahl | 3.5% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 7
VTGN · 92840H400
|
4.95% |
2/17/2026
Event 12/31/2025
|
|||
| Great Point Partners, LLC | 4.95% | ||||
| Dr. Jeffrey R. Jay, M.D. | 4.95% | ||||
| Ms. Lillian Nordahl | 4.95% | ||||
|
Zura Bio Ltd
13G/A
Amendment 2
ZURA · G9TY5A101
|
5.2% |
2/17/2026
Event 12/31/2025
|
|||
| Great Point Partners, LLC | 5.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||||
| Ms. Lillian Nordahl | 5.2% | ||||
|
Vor Biopharma Inc.
13G/A
Amendment 1
VOR · 929033207
|
3.3% |
2/17/2026
Event 12/31/2025
|
|||
| Great Point Partners, LLC | 3.3% | ||||
| Dr. Jeffrey R. Jay, M.D. | 3.3% | ||||
| Ms. Lillian Nordahl | 3.3% | ||||
|
Vor Biopharma Inc.
13G
VOR · 929033207
|
5.6% |
12/17/2025
Event 12/10/2025
|
|||
| Great Point Partners, LLC | 5.6% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.6% | ||||
| Ms. Lillian Nordahl | 5.6% | ||||
|
Zura Bio Ltd
13G/A
Amendment 1
ZURA · G9TY5A101
|
5.9% |
11/14/2025
Event 9/30/2025
|
|||
| Great Point Partners, LLC | 5.9% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.9% | ||||
| Ms. Lillian Nordahl | 5.9% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 6
VTGN · 92840H400
|
6.3% |
11/14/2025
Event 9/30/2025
|
|||
| Great Point Partners, LLC | 6.3% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.3% | ||||
| Ms. Lillian Nordahl | 6.3% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 4
UNCY · 90466Y202
|
4.5% |
11/14/2025
Event 9/30/2025
|
|||
| Great Point Partners, LLC | 4.5% | ||||
| Dr. Jeffrey R. Jay, M.D. | 4.5% | ||||
| Ms. Lillian Nordahl | 4.5% | ||||
|
ProMIS Neurosciences Inc.
13G/A
Amendment 4
PMN · 74346M406
|
10.0% |
11/14/2025
Event 9/30/2025
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
Inventiva S.A.
13G/A
Amendment 1
F5R343107
|
6.1% |
11/14/2025
Event 9/30/2025
|
|||
| Great Point Partners, LLC | 6.1% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.1% | ||||
| Ms. Lillian Nordahl | 6.1% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 5
CNTX · 21077P108
|
5.2% |
11/14/2025
Event 9/30/2025
|
|||
| Great Point Partners, LLC | 5.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||||
| Ms. Lillian Nordahl | 5.2% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 3
UNCY · 90466Y202
|
6.2% |
8/14/2025
Event 6/30/2025
|
|||
| Great Point Partners, LLC | 6.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.2% | ||||
| Ms. Lillian Nordahl | 6.2% | ||||
|
Outlook Therapeutics, Inc.
13G/A
Amendment 4
OTLK · 69012T305
|
4.99% |
8/14/2025
Event 6/30/2025
|
|||
| Great Point Partners, LLC | 4.99% | ||||
| Dr. Jeffrey R. Jay, M.D. | 4.99% | ||||
| Ms. Lillian Nordahl | 4.99% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 5
VTGN · 92840H400
|
6.6% |
8/14/2025
Event 6/30/2025
|
|||
| Great Point Partners, LLC | 6.6% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.6% | ||||
| Ms. Lillian Nordahl | 6.6% | ||||
|
ProMIS Neurosciences Inc.
13G/A
Amendment 3
PMN · 74346M406
|
10.0% |
8/14/2025
Event 6/30/2025
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 4
CNTX · 21077P108
|
5.2% |
8/14/2025
Event 6/30/2025
|
|||
| Great Point Partners, LLC | 5.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||||
| Ms. Lillian Nordahl | 5.2% | ||||
|
Inventiva S.A.
13G
F5R343107
|
7.4% |
6/20/2025
Event 5/5/2025
|
|||
| Great Point Partners, LLC | 7.4% | ||||
| Dr. Jeffrey R. Jay, M.D. | 7.4% | ||||
| Ms. Lillian Nordahl | 7.4% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 4
VTGN · 92840H400
|
6.7% |
5/15/2025
Event 3/31/2025
|
|||
| Great Point Partners, LLC | 6.7% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.7% | ||||
| Ms. Lillian Nordahl | 6.7% | ||||
|
Outlook Therapeutics, Inc.
13G/A
Amendment 3
OTLK · 69012T305
|
6.4% |
5/15/2025
Event 3/31/2025
|
|||
| Great Point Partners, LLC | 6.4% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.4% | ||||
| Ms. Lillian Nordahl | 6.4% | ||||
|
Optinose, Inc.
13G/A
Amendment 5
OPTN · 68404V209
|
4.9% |
5/15/2025
Event 3/31/2025
|
|||
| Great Point Partners, LLC | 4.9% | ||||
| Dr. Jeffrey R. Jay, M.D. | 4.9% | ||||
| Ms. Lillian Nordahl | 4.9% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 3
CNTX · 21077P108
|
5.2% |
5/15/2025
Event 3/31/2025
|
|||
| Great Point Partners, LLC | 5.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||||
| Ms. Lillian Nordahl | 5.2% | ||||
|
Zura Bio Ltd
13G
ZURA · G9TY5A101
|
5.1% |
5/14/2025
Event 5/8/2025
|
|||
| Great Point Partners, LLC | 5.1% | ||||
| Dr. Jeffrey R. Jay, M.D. | 5.1% | ||||
| Ms. Lillian Nordahl | 5.1% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 3
VTGN · 92840H400
|
6.9% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 6.9% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.9% | ||||
| Ms. Lillian Nordahl | 6.9% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 2
UNCY · 90466Y103
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
ProMIS Neurosciences Inc.
13G/A
Amendment 2
PMN · 74346M406
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 10.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 10.0% | ||||
| Ms. Lillian Nordahl | 10.0% | ||||
|
Outlook Therapeutics, Inc.
13G/A
Amendment 2
OTLK · 69012T305
|
8.2% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 8.2% | ||||
| Dr. Jeffrey R. Jay, M.D. | 8.2% | ||||
| Ms. Lillian Nordahl | 8.2% | ||||
|
Optinose, Inc.
13G/A
Amendment 4
OPTN · 68404V209
|
8.5% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 8.5% | ||||
| Dr. Jeffrey R. Jay, M.D. | 8.5% | ||||
| Ms. Lillian Nordahl | 8.5% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 2
CNTX · 21077P108
|
6.3% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 6.3% | ||||
| Dr. Jeffrey R. Jay, M.D. | 6.3% | ||||
| Ms. Lillian Nordahl | 6.3% | ||||
|
Zura Bio Limited
13G/A
Amendment 3
ZURA · G9TY5A101
|
4.9% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 4.9% | ||||
| Dr. Jeffrey R. Jay, M.D. | 4.9% | ||||
| Ms. Lillian Nordahl | 4.9% | ||||
|
Neurogene Inc.
13G/A
Amendment 3
NGNE · 64135M105
|
3.0% |
2/14/2025
Event 12/31/2024
|
|||
| Great Point Partners, LLC | 3.0% | ||||
| Dr. Jeffrey R. Jay, M.D. | 3.0% | ||||
| Ms. Lillian Nordahl | 3.0% | ||||